- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
SonoScape Launches Latest Generation Ultrasound System
The ELITE series merges artificial intelligence and augmented processing capabilities.
SonoScape Medical has launched its latest ultrasound system – the ELITE series, the company announced this week.
By combining artificial intelligence (AI) solutions and greater processing capabilities, the system is designed to improve diagnostic capabilities, company officials said.
“We developed the ELITE series in intensive cooperation with clinical experts,” said Zhou Wenping, head of research and development at SonoScape Medical. “I believe that this new series will substantially increase diagnostic confidence and empower clinicians to take advantage of the next level technologies, such as CEUS.”
SonoScape ELITE Courtesy: SonoScape Medical Corporation
This system adds AI-based automated tools, such as S-Fetus, Auto OB and lucid imaging technologies, as standard features on SonoScape’s Wis+ intelligent ultrasound platform. According to company details, the system offers four times the data processing capability and 10 times the system response rate of previous system iterations. In addition, it features advanced rendering models, including S-Live Silhouette and Color 3D.
The focus, officials said, is on optimizing image acquisition and diagnostic patient management workflows to help hospitals and clinics improve their performance, the experiences of their patients and staff, and health outcomes, while lowering the cost of care.
European Society of Breast Imaging Issues Updated Breast Cancer Screening Recommendations
April 24th 2024One of the recommendations from the European Society of Breast Imaging (EUSOBI) is annual breast MRI exams starting at 25 years of age for women deemed to be at high risk for breast cancer.
The Reading Room: Artificial Intelligence: What RSNA 2020 Offered, and What 2021 Could Bring
December 5th 2020Nina Kottler, M.D., chief medical officer of AI at Radiology Partners, discusses, during RSNA 2020, what new developments the annual meeting provided about these technologies, sessions to access, and what to expect in the coming year.
FDA Approves Fluorescence Imaging System for Detecting Residual Breast Cancer
April 18th 2024The combination of the optical imaging agent Lumisight and the fluorescence imaging device Lumicell Direct Visualization System, collectively known as LumiSystem, reportedly offers 84 percent accuracy with real-time detection of residual breast cancer after lumpectomy procedures.
